display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - L1 - all population
Immune checkpoint association
nivolumab plus ipilimumab CheckMate 069 ... CheckMate 067 ... CheckMate 067 ...
relatlimab plus nivolumab RELATIVITY-047

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons